Cryoport, a temperature-controlled logistics company, has opened its most recent global logistics centre in Amsterdam, The Netherlands.
The new centre adds to Cryoport’s global network supporting the distribution of biopharmaceutical products requiring exacting temperature and condition controls.
Cryoport’s ‘Chain of Compliance™’ processes will be employed at the new facility, Cryoport’s clients will benefit from the new global logistics centre.
“The demand for comprehensive global support of regenerative therapies is growing rapidly. We are happy to add Amsterdam to our global network with its excellent connectivity and reputation as one of Europe’s leading life sciences hubs,” said Jerrell Shelton, CEO of Cryoport.
“Choosing this strategic location for our newest global logistics centre allows us to more effectively support our global biopharmaceutical client base throughout the research, clinical and commercialisation phrases of their revolutionary regenerative therapies.”
“We would also like to thank the Dutch regulatory officials who worked so effectively to accommodate and welcome us to Amsterdam,” Shelton continued.
Amsterdam is a world-leading hub for the life sciences industry and supports the industry in many ways including the Amsterdam Science Park, an incubator for the development of healthcare businesses and special support of areas around the Schiphol Amsterdam Airport and the Port of Amsterdam, which offers strategic logistics hub locations.
Cryogenics logistics company Cryoport, Inc., will support TiGenix as it conducts its SEPCELL phase Ib/IIa clinical study to evaluate the safety and efficacy of expanded Cx611 allogeneic adipose‐derived stem cells (eASCs) for the treatment of sepsis in adult patients with severe community‐acquired bacterial pneumonia and admitted to the intensive care ...
McKesson Specialty Health, a division of McKesson Corporation, has announced a strategic collaboration with Cryoport, Inc. designed to further strengthen its robust logistics services to support the delivery of cell an gene therapies to patients at the point of care.
Month on month, the gasworld website is the market-leading news portal for the global industrial gas sector, growing at an unprecedented rate and keeping its readers at the forefront of breaking news, insightful analysis and must-see features across the industry. Launched in 2004 and continually evolving, it is the only independent online news, views and intelligence portal for the global industrial gas community and the larger end-user markets – and home to the ever-increasing range of gasworld platforms.
To find out more about gasworld's advertising opportunities click here.